Select one process architecture, scale or facility configuration only after product quality, material recovery, equipment fit, finite capacity, consumables, economics, environmental inventory and qualification evidence remain consistent.
Independent company use-case study · bioprocess technology
CytivaFive process decisions
Choose one use case. Add authorised plant data. Test capacity, cost and constraints.
Decision brief
One question. One model.
Authorised cell-culture or other feed basis through harvest, filtration, chromatography, concentration, formulation and bulk handoff, including buffers, assemblies, utilities, holds, waste and accepted product.
Five practical use cases
Five places to start.
Evaluation scopes for Cytiva—not claims of current software use.Compare complete bioprocess architectures
Connect cell culture, harvest, filtration, chromatography, concentration and formulation on one component, time, equipment, consumables and cost basis while preserving Cytiva tool boundaries.
Screen scale-up and facility fit
Translate authorised development evidence into mixing, gas-transfer, heat-removal, filter and column duties, then test those requirements against customer-supplied equipment, room and utility limits.
Schedule multi-product bioprocess trains
Sequence bioreactors, harvest and TFF systems, chromatography skids, buffer preparation, assemblies, laboratories and release holds without representing any Cytiva, Pall or customer schedule.
Compare single-use and hybrid lifecycle cases
Evaluate capital, consumables, cleaning, water, energy, waste, accepted output and greenhouse-gas inventory under one declared functional unit and transparent uncertainty ranges.
Connect component and validation evidence
Link requirements, component versions, regulatory statements, tests, risks, protocols, deviations and acceptance criteria while separating model review from supplier qualification and formal validation.
Action pack
Inputs in. Decisions out.
- Molecule, modality, quality, demand and production-mode basis
- Titer, recovery, flux, capacity, cycle and hold-time evidence
- Bioreactor, filter, chromatography, buffer and facility limits
- Consumables, utilities, waste, cost and lifecycle factors
- End-to-end bioprocess architecture comparison
- Scale-up and facility-fit evidence package
- Finite campaign and consumables plan
- TEA/LCA screen and component-evidence register
- Select one customer-authorised process decision.
- Declare modality, quality and system boundaries.
- Import development, equipment and facility evidence.
Evidence and limits
Public evidence only.
- Danaher — CytivaOfficial context for Cytiva as a Danaher operating company and the inclusion of Pall Life Sciences in its current scope.
- Cytiva — Online toolsOfficial context for Cytiva's existing bioreactor-scaling and process-intensification tools.
- Cytiva — Mechanistic chromatography modelingOfficial context for GoSilico and ChromX model calibration, validation and simulated chromatography experiments.
- Cytiva — Regulatory StatementsOfficial context for component documentation supporting customer qualification and risk assessment.
Guardrail: No Cytiva, Pall or customer process, deployment, integration, product configuration, facility, schedule, cost, environmental result, qualification or performance value is represented. Technology selection, supplier approval, validation, GxP and regulatory decisions remain within approved company and customer systems.